Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells

BACKGROUND: Chimeric antigen receptor-engineered T (CAR-T) cells have extraordinary effect in treating lymphoblastic leukemia. However, treatment of acute myeloid leukemia (AML) using CAR-T cells remains limited to date. Leukemogenesis always relates with the abnormalities of cytogenetics, and nearl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ying, Xu, Yingxi, Li, Saisai, Liu, Jia, Xing, Yanyan, Xing, Haiyan, Tian, Zheng, Tang, Kejing, Rao, Qing, Wang, Min, Wang, Jianxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930553/
https://www.ncbi.nlm.nih.gov/pubmed/29716633
http://dx.doi.org/10.1186/s13045-018-0603-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930553/
https://www.ncbi.nlm.nih.gov/pubmed/29716633
http://dx.doi.org/10.1186/s13045-018-0603-7

Ejemplares similares